Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ACCG-2671 in Obesity. The expected timing is based on the latest available company guidance and may change.
12/17/24- Selected as lead oral small molecule. 6/23/25- Present preclinical data at ADA '25. 8/6/25- Ph1 study initiation by YE 2025. 11/06/25:- IND-enabling activities are ongoing and first-in-human Ph1 initiation remains expected by YE 2025. 12/17/25:- Initiated first-in-human Ph1 SAD/MAD study in healthy volunteers and people with obesity. 02/26/26:- Initial Phase 1 SAD data from ACCG-2671 in obesity expected in H2 2026. 04/27/26:- ADA 2026 posters Jun 7: aleniglipron+ACCG-2671 NHP combo data; taste-avoidance profiles. 05/07/26:- Initial Phase 1 SAD data and MAD study initiation now expected around Q3 2026. 08/06/26:- Phase 1 SAD data and MAD trial initiation remain on track for Q3 2026. Combo trial starts Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.